Skip to main content
BFRI
NASDAQ Life Sciences

Biofrontera Posts $9.1M Q3 Revenue but Swings to $6.4M Net Loss

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.813
Mkt Cap
$13.752M
52W Low
$0.555
52W High
$1.66
52W Position info
47% above low
Off High info
51% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BFRI sits 47% above its 52-week low of $0.555 on light trading volume (0.3× avg).

Summary

Biofrontera reported Q3 revenue of $9.1 million, up 30% on higher Ameluz sales, alongside a $6.4 million net loss, or $0.42 per share, and negative adjusted EBITDA of $5.5 million. The loss lands against a going-concern warning disclosed in the last 10-Q, so the cash burn is the number that matters here, not the top line. This is the first quarterly report since the September 8-K disclosing FDA approval of Ameluz for superficial basal cell carcinoma, and the October supplemental NDA filing to expand the red-light photodynamic therapy label — neither has yet shown up in revenue. With the stock at $0.81 and a micro-cap valuation, the company's ability to fund the launch without fresh capital is the open question. No specific date for the next filing or financing update was provided.

At the time of this announcement, BFRI was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $0.55 to $1.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BFRI - Latest Insights

BFRI
Nov 13, 2026, 4:46 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.700
Real-time Price: $0.660 info
Change: -$0.040 (-6%) info
Market Cap: $10.398M info
BFRI
Oct 08, 2026, 9:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.9722
Real-time Price: $0.660 info
Change: -$0.3122 (-32%) info
Market Cap: $10.398M info
BFRI
Sep 14, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $0.660 info
Change: -$0.890 (-57%) info
Market Cap: $10.398M info
BFRI
Aug 13, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.27
Real-time Price: $0.660 info
Change: -$0.610 (-48%) info
Market Cap: $10.398M info
BFRI
Aug 13, 2026, 8:51 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.660 info
Change: -$0.580 (-47%) info
Market Cap: $10.398M info